908 Devices reported preliminary fourth‑quarter 2025 revenue of $17.2 million, a 20% year‑over‑year increase that follows a $14.0 million quarter in Q3 2025 and a $18.8 million quarter in Q4 2024. The growth was driven by a surge in VipIR sales, stronger demand in U.S. state and local channels, and expanding federal and defense contracts, while international sales also accelerated as the company ramps adoption of VipIR abroad.
Full‑year 2025 revenue was $56.0 million, up 17% from the audited $47.7 million in 2024 and exceeding the consensus estimate of $54.77 million. The year‑long lift was largely supported by continued momentum in the state and local segment, growing federal and defense revenue, and the international expansion of VipIR, which together offset any headwinds in legacy product lines.
The company achieved its first adjusted EBITDA positivity in Q4 2025, a milestone that signals a successful transition toward profitability. The improvement in profitability stems from disciplined cost reductions, a product‑mix shift toward higher‑margin VipIR units, and a 58% gross margin in Q3 2025 that represents a recovery from the prior year’s mix‑related compression. These measures collectively lifted the adjusted EBITDA margin to a positive figure for the quarter.
Kevin J. Knopp, CEO and co‑founder, said the results confirm the company’s 2025 transformation: “In 2025, we transformed our company into a stronger, simpler, and more profitable financial model focused on frontline chemical detection. We achieved strong top‑line growth and our goal to be Adjusted EBITDA positive in the fourth quarter. These solid results and powerful macro trends, including increased funding to combat the fentanyl and opioid crisis and increased global defense budgets, position us well for future growth.”
Analysts had expected Q4 revenue of $15.92 million; the company beat that estimate by $1.28 million. The full‑year revenue consensus was $54.77 million, and the company exceeded that by $1.23 million. The results were well received by investors, reflecting confidence in the company’s strategic focus and execution.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.